Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Christopher Alexander Hinze, Rainer Ehmann, Margret Jandl, Katrin Milger, Olaf Schmidt, Christian Schulz, Dirk Skowasch, Tobias Welte, Roland Buhl, Eckard Hamelmann, Marco Idzko, Christian Taube, Stephanie Korn, Hendrik Suhling
After the GINA update in 2019, the proportion of SMART therapy increased with evidence for better disease control in SMART patients compared to SABA alone https://bit.ly/3SSPX1C.
March 2024: ERJ Open Research
#22
JOURNAL ARTICLE
Tasmin Barry, Mark Holliday, Jenny Sparks, Rowan Biggs, Atalie Colman, Rebekah Lamb, Karen Oldfield, Nick Shortt, Kyley Kerse, John Martindale, Allie Eathorne, Michaela Walton, Bianca Black, Matire Harwood, Pepa Bruce, Ruth Semprini, Andrew Bush, Louise Fleming, Catherine A Byrnes, David McNamara, Lee Hatter, Stuart R Dalziel, Mark Weatherall, Richard Beasley
BACKGROUND: Asthma is the most common chronic childhood respiratory condition globally. Inhaled corticosteroid (ICS)-formoterol reliever-based regimens reduce the risk of asthma exacerbations compared with conventional short-acting β2 -agonist (SABA) reliever-based regimens in adults and adolescents. The current limited evidence for anti-inflammatory reliever therapy in children means it is unknown whether these findings are also applicable to children. High-quality randomised controlled trials (RCTs) are needed...
March 2024: ERJ Open Research
#23
JOURNAL ARTICLE
Connie L Yang, Zofia Zysman-Colman, Estelle Chétrit, Anne Hicks, Joseph Reisman, Amy Glicksman
This practice point summarizes recommendations from the Canadian Thoracic Society's 2021 "Guideline update: Diagnosis and management of asthma in preschoolers, children, and adults." New recommendations include: a decrease in the frequency of daytime symptoms and reliever use to ≤2 per week in the asthma control criteria; assessing for risk of asthma exacerbation; not using as-needed short-acting beta-agonists alone in patients at higher risk for exacerbation; and the option of as-needed budesonide/formoterol (bud/form) in those ≥12 years old if they are unable to take daily inhaled corticosteroids despite extensive asthma education and support...
May 2024: Paediatrics & Child Health
#24
JOURNAL ARTICLE
Manuela Latorre, Angela Rizzi, Pierluigi Paggiaro, Ilaria Baiardini, Diego Bagnasco, Stefano DelGiacco, Carlo Lombardi, Vincenzo Patella, Eleonora Nucera, Roberta Parente, Giovanni Paoletti, Laura Pini, Erminia Ridolo, Gianenrico Senna, Francesco Blasi, Giorgio Walter Canonica, Arianna Aruanno, Carmen Ballacchino, Marco Bonavia, Cecilia Calabrese, Marco Caminati, Monica Carbonara, Cristina Cardini, Cristiano Caruso, Luciano Cattani, Maria Angiola Crivellaro, Alessandra Diana, Eugenia Durante, Elisabetta Favero, Maria Pia Foschino Barbaro, Sandra Frateiacci, Gabriella Guarnieri, Alessia Lofaro, Francesca Losa, Nadia Magarò, Francesco Menzella, Luisa Ricciardi, Giulia Scioscia, Elisa Testino, Francesca Torracca
OBJECTIVE: Patients' perceptions of asthma symptoms, and attitudes regarding diagnosis and management, can affect their ability to reach good asthma control. The aim of the study was to explore patients' perceptions of asthma management, with focus on treatment with oral corticosteroids (OCS). METHODS: A DOXAPHARMA survey was conducted. A questionnaire with 46 multiple choice questions was completed by 50 patients with severe uncontrolled asthma, and 258 with mild-moderate controlled or partly controlled asthma...
April 5, 2024: Journal of Asthma
#25
JOURNAL ARTICLE
Kefang Lai, Dejun Sun, Ranran Dai, Ronnie Samoro, Hae-Sim Park, Annika Åstrand, David Cohen, Maria Jison, Vivian H Shih, Viktoria Werkström, Yuhui Yao, Yajuan Zhang, Wenying Zheng, Nanshan Zhong, Albay Albert, Bo Jianping, Chen Bi, Chen Lijun, Chen Mei, Chen Min, Chen Ping, Chen Zhimin, Chian Chih-Feng, Cho You Sook, Fu Xiuhua, Gao Xiwen, Gu Wei, Han Wei, Han Zhihai, Hu Xi Wei, Huang Kewu, Huang Mao, Isidro Marie Grace Dawn, Jeong Inbeom, Jiang Luning, Jiang Mingyan, Jiang Shanping, Jin Meiling, Kang Jian, Kim Jin Woo, Kim Sang-Ha, Kuang Jiulong, Kuo Ping-Hung, Li Jie, Li Manxiang, Li Minjing, Li Ruoran, Li Wen, Li Xianhua, Li Yanming, Lim Seong Yong, Liu Chuanhe, Liu Chuntao, Liu Jing, Liu Xiaoxia, Lu Huiyu, Luo Zhuang, Ma Shengxi, Mao Liangping, Min Kyung Hoon, Mu Lin, Park Choon-Sik, Park Hae Sim, Park Hye-Kyung, Park Jung-Won, Perng Diahn-Warng, Samoro Ronnie, Shi Guochao, Sun Debin, Sun Dejun, Wang Chun-Hua, Wang Guangfa, Wang Limin, Wang Xuefen, Wang Yan, Wei Liping, Wu Haihong, Xiao Yi, Xiao Zuke, Xie Canmao, Xu Jin-Fu, Xu Xingxiang, Xu Xiyuan, Yan Jianping, Yang Hongzhong, Yoon Ho Joo, Yu Wencheng, Zhang Jin, Zhang Longju, Zhang Min, Zhang Wei, Zhao Jianping, Zhao Ziwen, Zhu Xiaoli, Zhu Yingqun
BACKGROUND: Benralizumab is indicated as add-on therapy in patients with uncontrolled, severe eosinophilic asthma; it has not yet been evaluated in a large Asian population with asthma in a clinical trial. OBJECTIVE: To evaluate the efficacy and safety of benralizumab in patients with severe asthma in Asia. METHODS: MIRACLE (NCT03186209) was a randomized, Phase 3 study in China, South Korea, and the Philippines. Patients aged 12-75 years with severe asthma receiving medium-to-high-dose inhaled corticosteroid/long-acting β2 -agonists, stratified (2:1) by baseline blood eosinophil count (bEOS) (≥300/μL; <300/μL), were randomized (1:1) to benralizumab 30 mg or placebo...
April 1, 2024: Respiratory Medicine
#26
REVIEW
Leslie Hendeles, Miles Weinberger
No abstract text is available yet for this article.
March 29, 2024: Paediatric Respiratory Reviews
#27
JOURNAL ARTICLE
Danny Darmawan, Iris Rengganis, Cleopas Martin Rumende, Hamzah Shatri, Soekamto Koesnoe, Yogi Umbarawan, Rudi Putranto, Sally Aman Nasution
BACKGROUND: Asthma is a disease characterized by chronic airway inflammation, however one-third of asthmatic cases did not respond adequately. Inhaled magnesium has been proposed as a treatment for unresponsive asthma cases. However, its role remains controversial. This review evaluates the effectiveness and safety of nebulized magnesium compared to standard therapy (Beta Agonist, Anticholinergic, Corticosteroid) in adults with acute asthma attacks. METHODS: The protocol has been registered in PROSPERO...
January 2024: Acta Medica Indonesiana
#28
JOURNAL ARTICLE
Arzu Yorgancıoğlu, Alvaro A Cruz, Gabriel Garcia, Kim L Lavoie, Nicolas Roche, Manish Verma, Anurita Majumdar, Swarnendu Chatterjee
INTRODUCTION/BACKGROUND: Mild asthma treatment recommendations include intermittent inhaled corticosteroid (ICS)/formoterol dosing or regular ICS dosing with short-acting β2 -agonist reliever. Due to the heterogeneity of asthma, identification of traits associated with improved outcomes to specific treatments would be clinically beneficial. AIMS/OBJECTIVES: To assess the impact of patient traits on treatment outcomes of regular ICS dosing compared with intermittent ICS/formoterol dosing, a systematic literature review (SLR) and network meta-analysis (NMA) was conducted...
March 30, 2024: Respiratory Medicine
#29
RANDOMIZED CONTROLLED TRIAL
Matthew B Stanbrook
Jackson DJ, Heaney LG, Humbert M, et al; SHAMAL Investigators. Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study. Lancet. 2024;403:271-281. 38071986.
April 2024: Annals of Internal Medicine
#30
JOURNAL ARTICLE
Linnea Hedman, Martin Andersson, Anders Bjerg, Helena Backman, Maja Af Klinteberg, Anna Winberg, Eva Rönmark
BACKGROUND: In the present study, we describe prevalence trends of asthma and investigate the association with asthma symptoms, use of asthma medication, and asthma severity among 8-year-old children in Norrbotten, Sweden in 1996, 2006, and 2017. METHODS: Within the Obstructive Lung Disease in Northern Sweden (OLIN) studies, three pediatric cohorts were recruited in 1996, 2006, and 2017 respectively. Identical methods were used; all children in first and second grade (median age 8 years) in three municipalities were invited to a parental questionnaire survey, completed by n = 3430 in 1996 (97% participation), n = 2585 in 2006 (96%), and n = 2785 in 2017 (91%)...
April 2024: Pediatric Allergy and Immunology
#31
JOURNAL ARTICLE
Cataldo Martucci, Andrew Dennis Allen, Nadia Moretto, Valentina Bagnacani, Alessandro Fioni, Riccardo Patacchini, Maurizio Civelli, Gino Villetti, Fabrizio Facchinetti
Inhibition of p38 mitogen-activated protein kinase (MAPKs) is a potential therapeutic approach for the treatment of acute and chronic pulmonary inflammatory conditions. Here, we report the in vitro and in vivo characterization of the anti-inflammatory effects of CHF6297, a novel potent and selective p38α inhibitor designed for inhalation delivery as a dry powder formulation. CHF6297 has been proven to inhibit p38α enzymatic activity with sub-nanomolar potency (IC50 = 0.14 ± 0.06 nM), with >1,000-fold selectivity against p38γ and p38δ...
2024: Frontiers in Pharmacology
#32
JOURNAL ARTICLE
Catalina Lizano-Barrantes, Olatz Garin, Karina Mayoral, Alexandra L Dima, Angels Pont, María Araceli Caballero-Rabasco, Manuel Praena-Crespo, Laura Valdesoiro-Navarrete, María Teresa Guerra, Alberto Bercedo-Sanz, Montse Ferrer
Introduction: We aimed to evaluate the longitudinal relationships, both at between- and within-person levels, that adherence to inhaled corticosteroid-based maintenance treatment and inhalation technique present with symptom control, exacerbations, and health-related quality of life (HRQoL) in children and adolescents with asthma. Methods: Participants (6-14 years old) from the ARCA (Asthma Research in Children and Adolescents) cohort-a prospective, multicenter, observational study (NCT04480242)-were followed for a period from 6 months to 5 years via computer-assisted telephone interviews and a smartphone application...
2024: Frontiers in Pharmacology
#33
JOURNAL ARTICLE
Beth A Zerr, Jacklyn M Kruse, Jon J Glover
BACKGROUND: A significant update was made to both the Global Initiative for Asthma (GINA) in 2019 and the National Heart Lung and Blood Institute (NHLBI) asthma guidelines in 2020 for mild asthma. These groups no longer recommend short-acting beta-agonists (SABA) as monotherapy for mild (GINA) or mild-persistent (NHLBI) asthma. With the lag that can occur between guideline or evidence updates and changes in practice, this study sought to evaluate whether guideline adoption had occurred...
March 28, 2024: Allergy, Asthma, and Clinical Immunology
#34
JOURNAL ARTICLE
Hector Rojas-Anaya, Akshat Kapur, Graham Roberts, Damian Roland, Atul Gupta, Michaela Lazner, Jane Bayreuther, John Pappachan, Christina Jones, Stephen Bremner, Fleur Cantle, Paul Seddon
BACKGROUND: Acute severe asthma (ASA) is a leading cause of hospital attendance in children. Standard first-line therapy consists of high-dose inhaled bronchodilators plus oral corticosteroids. Treatment for children who fail to respond to first-line therapy is problematic: the use of intravenous agents is inconsistent, and side effects are frequent. High-flow humidified oxygen (HiFlo) is widely used in respiratory conditions and is increasingly being used in ASA, but with little evidence for its effectiveness...
March 28, 2024: JMIR Research Protocols
#35
Bianca Oprescu, Oana Raduna, Stefan Mihaicuta, Stefan Frent
Background and Objectives : Severe adult-onset eosinophilic asthma and COPD with eosinophilic inflammation are two entities with a similar clinical course and are sometimes difficult to differentiate in clinical practice, especially in patients with a history of smoking. Anti-IL-5 or -IL-5R biological therapy has been shown to be highly effective in severe eosinophilic asthma but has not demonstrated significant benefit in patients with COPD with the eosinophilic phenotype. Our aim was to illustrate this issue in the form of a case report...
February 25, 2024: Medicina
#36
JOURNAL ARTICLE
Mei-Sing Ong, Joanne E Sordillo, Amber Dahlin, Michael McGeachie, Kelan Tantisira, Alberta L Wang, Jessica Lasky-Su, Murray Brilliant, Terrie Kitchner, Dan M Roden, Scott T Weiss, Ann Chen Wu
BACKGROUND: Although inhaled corticosteroids (ICS) are the first-line therapy for patients with persistent asthma, many patients continue to have exacerbations. We developed machine learning models to predict the ICS response in patients with asthma. METHODS: The subjects included asthma patients of European ancestry ( n = 1371; 448 children; 916 adults). A genome-wide association study was performed to identify the SNPs associated with ICS response. Using the SNPs identified, two machine learning models were developed to predict ICS response: (1) least absolute shrinkage and selection operator (LASSO) regression and (2) random forest...
February 25, 2024: Journal of Personalized Medicine
#37
JOURNAL ARTICLE
Pan-Pan Xie, Yue Zhang, Wen-Kai Niu, Bo Tu, Ning Yang, Yun Fang, Ying-Hui Shi, Fu-Sheng Wang, Xin Yuan
BACKGROUND: Chronic cough is a common symptom in patients post the coronavirus disease 2019 (COVID-19). In this study, we aimed to investigate the efficacy of inhaled corticosteroids (ICS) and the clinical characteristics of patients with post-COVID-19 chronic cough during the Omicron era. METHODS: An ambispective, longitudinal cohort study was conducted that included patients with post-COVID-19 who attended the respiratory clinic at our hospital between January 1, 2023, and March 31, 2023 with a complaint of persistent cough lasting more than 8 weeks...
March 27, 2024: BMC Pulmonary Medicine
#38
JOURNAL ARTICLE
Peter T Daley-Yates, Bhumika Aggarwal, Maximilian Plank
INTRODUCTION: Asthma treatment guidelines classify inhaled corticosteroid (ICS) regimens as low, medium, or high dose. However, efficacy and safety are not independently assessed accordingly. Moreover, differences in ICS duration of action are not considered when a dose regimen is selected. We investigated the efficacy and safety implications of these limitations for available ICS molecules. METHODS: Published pharmacodynamic and pharmacokinetic parameters were used, alongside physiological and pharmacological principles, to estimate the efficacy and safety of available ICS molecules...
March 27, 2024: Advances in Therapy
#39
JOURNAL ARTICLE
Sangmin Lee, Erin Hetherington, Richard Leigh, Kaylee Ramage, Amy Metcalfe
BACKGROUND: Asthma affects 5% to 13% of pregnant women, and many require daily pharmacotherapy to achieve asthma control; however, adherence to medication during pregnancy often decreases. OBJECTIVE: To understand the association between the use of or adherence to asthma medication with asthma exacerbation and maternal/neonatal outcomes. METHODS: Using linked population-based administrative databases from Alberta, Canada (2012-2018), pregnant women with asthma were categorized based on asthma medication use 1 year before pregnancy: short-acting β-agonists (SABA), inhaled corticosteroids (ICS), and ICS with long-acting β-agonists (ICS+LABA)...
March 7, 2024: Journal of Allergy and Clinical Immunology in Practice
#40
REVIEW
Reynold Panettieri, Njira Lugogo, Jonathan Corren, Christopher S Ambrose
Asthma is a heterogeneous inflammatory disease of the airways, affecting many children, adolescents, and adults worldwide. Up to 10% of people with asthma have severe disease, associated with a higher risk of hospitalizations, greater healthcare costs, and poorer outcomes. Patients with severe asthma generally require high-dose inhaled corticosteroids and additional controller medications to achieve disease control; however, many patients remain uncontrolled despite this intensive treatment. The treatment of severe uncontrolled asthma has improved with greater understanding of asthma pathways and phenotypes as well as the advent of targeted biologic therapies...
2024: Journal of Asthma and Allergy
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
